Compare KFRC & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KFRC | VNDA |
|---|---|---|
| Founded | 1962 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.7M | 411.3M |
| IPO Year | 1996 | 2005 |
| Metric | KFRC | VNDA |
|---|---|---|
| Price | $43.31 | $7.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $39.67 | $14.90 |
| AVG Volume (30 Days) | 322.3K | ★ 1.0M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.42% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $1,329,007,000.00 | $216,105,000.00 |
| Revenue This Year | $2.78 | $21.35 |
| Revenue Next Year | $4.32 | $37.40 |
| P/E Ratio | $96.28 | ★ N/A |
| Revenue Growth | N/A | ★ 8.72 |
| 52 Week Low | $24.49 | $3.81 |
| 52 Week High | $47.50 | $9.91 |
| Indicator | KFRC | VNDA |
|---|---|---|
| Relative Strength Index (RSI) | 70.86 | 57.39 |
| Support Level | $26.60 | $7.12 |
| Resistance Level | $47.48 | $7.79 |
| Average True Range (ATR) | 2.12 | 0.28 |
| MACD | 1.33 | 0.07 |
| Stochastic Oscillator | 75.82 | 98.99 |
Kforce Inc is a solutions firm specializing in technology, finance, accounting, and other professional staffing services. The company operates two business segments: the Technology segment, which provides talent solutions with candidates skilled in areas including systems/applications architecture and development, data management and analytics, business and artificial intelligence, machine learning, project and program management, and network architecture and security. The FA segment offers consultants in traditional finance and accounting roles such as finance, planning and analysis; business intelligence analysis; general accounting; transactional accounting, business and cost analysis; and taxation and treasury. The majority of revenue is earned through the Technology segment.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.